In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d
- PMID: 37011390
- DOI: 10.7326/J23-0020
In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d
Abstract
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.
Comment on
-
Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial.JAMA. 2023 Jan 3;329(1):39-51. doi: 10.1001/jama.2022.23257. JAMA. 2023. PMID: 36525245 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous